Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives $42.00 Consensus Target Price from Analysts

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has received an average rating of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $40.8571.

LYEL has been the topic of several recent analyst reports. Citizens Jmp reissued a “market outperform” rating and issued a $34.00 target price on shares of Lyell Immunopharma in a report on Monday, June 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price target on shares of Lyell Immunopharma in a report on Monday, June 15th. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of Lyell Immunopharma in a report on Tuesday, June 9th. Finally, Stifel Nicolaus assumed coverage on Lyell Immunopharma in a research report on Thursday, August 6th. They set a “buy” rating and a $36.00 target price on the stock.

Institutional Trading of Lyell Immunopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new stake in shares of Lyell Immunopharma during the 2nd quarter worth approximately $347,000. Bank of America Corp DE boosted its stake in Lyell Immunopharma by 314.2% in the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock valued at $668,000 after acquiring an additional 25,276 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Lyell Immunopharma by 194.8% in the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after acquiring an additional 76,921 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of Lyell Immunopharma during the first quarter worth about $445,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Lyell Immunopharma during the first quarter worth about $959,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Trading Down 2.9%

Shares of NASDAQ LYEL opened at $13.55 on Thursday. The stock has a market cap of $331.98 million, a P/E ratio of -1.06 and a beta of -0.04. Lyell Immunopharma has a 12-month low of $10.49 and a 12-month high of $45.00. The business’s fifty day simple moving average is $13.50 and its 200-day simple moving average is $18.52.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.94) by $0.02. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%.The business had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.00 million. On average, equities analysts forecast that Lyell Immunopharma will post -7.18 EPS for the current fiscal year.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.